and 1 other(s)
Background and Aims: PCSK-9-Inhibitors have become available for treating hypercholesterolaemia and have been clinically used in Denmark since October 2015. We have no prior practical experience from real-life clinical use. In Denmark national guidelines regulates the use of PCSK9-Inhibitors. We aim to describe the patient demography, the effect of the treatment and the effects on organ markers (Creatinine, Hba1c or ALAT), in a real-life population. Methods: All Danish lipid clinics were contacted and asked to collect data on patients prescribed with PCSK-9-Inhibitors between October 1st, 2015 and May 1st, 2018. Plasma lipids and lipoproteins (LDL-C, triglyceride, HDL-C) and organ markers were measured at baseline and follow up visits. Absolute changes were recorded and means compared. Results Nationwide, 12 clinics participated in providing data on 383 patients; estimated 90% of all patients treated with PCSK9-Inhibitors in Denmark. An overall significant reduction of LDL-C from 5,11 mmol/L to 2.50 mmol/L (48,9.0%) was observed after only one month. This level persisted throughout the observation period, comparable to the two major outcome studies (FOURIER and ODYSSEY). No changes were found in relation to other plasma lipids or organ markers over time. Unlike the population in the outcome studies, only 94 received statins along with PCSK-9-Inhibitors. A large proportion were statin intolerant (n=243). Conclusions: Even though the real-life population do not match the populations previously examined by the two major outcome studies, we find a comparable reduction of LDL-C. PCSK-9-Inhibitors had no effect on triglyceride, HDL-C, Creatinine, HbA1c ALAT during the two years observation period.
No datasets are available for this submission.
No license information is available for this submission.